Skip to search formSkip to main contentSkip to account menu

ESHAP protocol

Known as: Cisplatin/Cytarabine/Etoposide/Methylprednisolone, ARA-C/CDDP/MePRDL/VP-16, E-SHAP 
National Institutes of Health

Related topics

Related topics

5 relations
CisplatinCytarabineESAP protocolEtoposide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A…
Introduction: 30% of Hodgkin Lymphoma (HL) patients are refractory or relapse (RR) after first line therapy. Salvage chemotherapy… 
2016
2016
Phase II trial of ofatumumab plus ESHAP (O‐ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first‐line chemotherapy
The management of recurrent/refractory (R/R) Hodgkin lymphoma (HL) remains challenging. Previously published data have shown some… 
2010
2010
A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for…
2010
2010
ESHAP versus rituximab-ESHAP in frail patients with refractory diffuse large B-cell lymphoma.
BACKGROUND Treatment for refractory lymphoma in frail patients (older, poor performance status, or concomitant diseases) has not… 
Review
2008
Review
2008
Evidence of a graft-versus-Hodgkin lymphoma effect in the setting of extensive bone marrow involvement.
2006
2006
ESHAP+fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of…
From 1996 to November 2004, 131 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin's… 
Review
2004
Review
2004
Improving second-line therapy in aggressive non-Hodgkin's lymphoma.
The prognosis is poor for patients relapsing following treatment with standard chemotherapy for aggressive non-Hodgkin's lymphoma… 
Highly Cited
2002
Highly Cited
2002
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Treatment for patients with stage IV indolent lymphoma ranges from watchful waiting to intensive chemotherapy and stem cell… 
1999
1999
Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients.
This study was designed to assess the results of protracted courses of ESHAP (etoposide, cytarabine, cisplatin… 
1996
1996
Autologous bone marrow transplantation in relapsed HIV-related non-Hodgkin's lymphoma.
There are few reports of salvage chemotherapy for HIV-related non-Hodgkin's lymphoma (NHL). We report a relapsed HIV-related high… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)